Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep;24(9):1828-1830.
doi: 10.1007/s12094-022-02838-3. Epub 2022 May 11.

Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence

Douglas Guedes de Castro  1 , Carlos Henrique Andrade Teixeira  2 , Guilherme Rocha Melo Gondim  3 , Patrícia Bailão Aguilar  3 , Marcos André de Sá Barreto Costa  2 , Thiago William Carnier Jorge  2 , Rodrigo de Morais Hanriot  3
Affiliations

Impact of cranial stereotactic radiotherapy associated with immunotherapy with nivolumab and ipilimumab on overall survival in patients with melanoma brain metastases: a real-world evidence

Douglas Guedes de Castro et al. Clin Transl Oncol. 2022 Sep.

Abstract

Purpose: To evaluate the impact of cranial stereotactic radiotherapy (SRT) on overall survival (OS) of melanoma brain metastases (MBM) patients treated with combined nivolumab and ipilimumab (CNI) in a contemporary and real-world setting.

Methods/patients: The study was performed by using TriNetX, a global health network dataset of electronic medical records from patients in 49 healthcare organizations. We queried for patients with specific terms between January 2016 and December 2020 and run a propensity score matching (PSM) analysis. OS was estimated by Kaplan-Meier and log-rank test was applied.

Results: After initial query and PSM, 114 patients were selected in each cohort. Median OS was 327 days in CNI and not reached in the CNI + SRT cohort, with OS probability of 54.4 and 40.9%, respectively (log-rank P = .0057). CNI + SRT was associated with significantly decreased mortality (HR, 0.57; 95% CI 0.377-0.853; proportionality P = .0034).

Conclusions: This real-world analysis showed that CNI + SRT led to an improvement in OS compared to CNI.

Keywords: Brain metastases; Immunotherapy; Melanoma; Radiosurgery.

PubMed Disclaimer

References

    1. Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–30. https://doi.org/10.1056/NEJMoa1805453 . - DOI - PubMed - PMC
    1. Sperduto PW, Mesko S, Li J, et al. Survival in patients with brain metastases: summary report on the updated diagnosis-specific graded prognostic assessment and definition of the eligibility quotient. J Clin Oncol. 2020;38(32):3733–84. https://doi.org/10.1200/JCO.20.01255 . - DOI
    1. Shinde A, Li R, Amini A, Glaser S. Can immunotherapy replace radiotherapy in melanoma brain metastases? J Clin Oncol. 2019;37(12):1030–1. https://doi.org/10.1200/JCO.18.01982 . - DOI - PubMed
    1. Hong AM, Fogarty GB, Dolven-Jacobsen K, et al. Adjuvant whole-brain radiation threrapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase iii trial. J Clin Oncol. 2019;37(33):3132–41. https://doi.org/10.1200/JCO.19.01414 . - DOI - PubMed
    1. Amaral T, Kiecker F, Schaefer S, et al. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients. J Immunother Cancer. 2020;8(1): e000333. https://doi.org/10.1136/jitc-2019-000333 . - DOI - PubMed - PMC

LinkOut - more resources